Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A
Folia Biol (Praha). 1986;32(3):183-94.
Highly purified recombinant human interleukin 2 induced cytotoxicity of lymphocytes from urinary bladder carcinoma patients and from control healthy donors when added during an 18-h 51Cr microcytotoxicity assay against bladder carcinoma (T24) target cells. Similar levels of killer cell activation were detected in mononuclear cell preparations from bladder carcinoma patients and control healthy donors; hence, no defect in the responsiveness of bladder carcinoma patients' lymphocytes to interleukin 2 could be observed. The effect of the recombinant interleukin 2 was dose-dependent. Addition of monoclonal antibody 7E9 directed against cell-type restricted antigen associated with the T24 target cells and capable of inducing antibody-dependent cellular cytotoxicity could not increase the cytotoxicity-inducing effects of interleukin 2.
在针对膀胱癌（T24）靶细胞进行的18小时51Cr微量细胞毒性试验中添加高度纯化的重组人白细胞介素2时，可诱导来自膀胱癌患者和对照健康供体的淋巴细胞产生细胞毒性。在膀胱癌患者和对照健康供体的单核细胞制剂中检测到相似水平的杀伤细胞激活；因此，未观察到膀胱癌患者淋巴细胞对白介素2的反应性存在缺陷。重组白介素2的作用呈剂量依赖性。添加针对与T24靶细胞相关的细胞类型限制性抗原且能够诱导抗体依赖性细胞毒性的单克隆抗体7E9，不能增强白介素2的细胞毒性诱导作用。
